Company info
We are a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antimicrobial therapeutics for multidrug-resistant (“MDR”) “superbug” infections. The World Health Organization (“WHO”) lists 12 MDR bacteria (“superbugs”) that pose the greatest risks to public health. Since our inception in 2007, leveraging our management team’s extensive experience in the discovery and development of novel antimicrobial agents, our scientists in the United States and China have built a pipeline of four antimicrobial drug candidates (contezolid (MRX-I), contezolid acefosamil (MRX-4), MRX-8, and MRX-10) intended to combat various pathogens on the WHO list of “superbugs”.
Address: Floor 3 Building B, 1976 GaokeZhong Road, Pudong, Shanghai, China
Tel : +86 21 51370606
Website: http://www.micurxchina.com/